207_Combined course Presentations

Role of Immunotherapy in Hodgkin Lymphoma

Brentuximab Vedotin (SGN-35) Mechanism of action

protease-cleavable linker monomethyl auristatin E (MMAE), potent antitubulin agent

anti-CD30 monoclonal antibody

Antibody drug conjugate binds to CD30

ADC-CD30 complex traffics to lysosome

MMAE is released

G2/M cell cycle arrest

MMAE disrupts Microtubule network

Apoptosis